Current state of play for HPV-positive oropharyngeal cancers.

Deutsch, F; Regina Bullen, I; Nguyen, K; Tran, N-H; Elliott, M; Tran, N

Current state of play for HPV-positive oropharyngeal cancers.

Deutsch, F Regina Bullen, I Nguyen, K Tran, N-H Elliott, M Tran, N

Permalink

Publisher:: ELSEVIER SCI LTD
Publication Type:: Journal Article
Citation:: Cancer Treat Rev, 2022, 110, pp. 102439
Issue Date:: 2022-11

Closed Access

	Filename	Description	Size
	Current state of play for HPV-positive oropharyngeal cancers..pdf	Published version	1.88 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Deutsch, F
dc.contributor.author	Regina Bullen, I
dc.contributor.author	Nguyen, K
dc.contributor.author	Tran, N-H
dc.contributor.author	Elliott, M
dc.contributor.author	Tran, N https://orcid.org/0000-0001-7747-2530
dc.date.accessioned	2023-03-21T02:44:20Z
dc.date.available	2022-07-17
dc.date.available	2023-03-21T02:44:20Z
dc.date.issued	2022-11
dc.identifier.citation	Cancer Treat Rev, 2022, 110, pp. 102439
dc.identifier.issn	0305-7372
dc.identifier.issn	1532-1967
dc.identifier.uri	http://hdl.handle.net/10453/167915
dc.description.abstract	Clinically, HPV-positive oropharyngeal cancers (OPCs) have been shown to have a distinct prognosis, compared to HPV-negative tumours, particularly in survival rates and responses to treatment. These patients have better survival chances and improved prognosis, indicating that a more exhaustive knowledge of these distinctions would aid in the discovery of clinical approaches for both HPV-positive and negative tumours. Furthermore, there is increasing evidence that HPV-related oropharyngeal cancers constitute an epidemiological, molecular, and clinical distinct form as compared to non-HPV related ones therefore, the treatment of these specific subtype of oropharyngeal cancers should adopt a distinct clinical treatment pipeline. Our review will examine the current approaches for the diagnosis and treatment of OPC and discuss the relevance of de-escalation clinical trials in progress.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	ELSEVIER SCI LTD
dc.relation.ispartof	Cancer Treat Rev
dc.relation.isbasedon	10.1016/j.ctrv.2022.102439
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1112 Oncology and Carcinogenesis
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.mesh	Humans
dc.subject.mesh	Oropharyngeal Neoplasms
dc.subject.mesh	Papillomaviridae
dc.subject.mesh	Papillomavirus Infections
dc.subject.mesh	Prognosis
dc.subject.mesh	Survival Rate
dc.subject.mesh	Humans
dc.subject.mesh	Papillomaviridae
dc.subject.mesh	Papillomavirus Infections
dc.subject.mesh	Oropharyngeal Neoplasms
dc.subject.mesh	Prognosis
dc.subject.mesh	Survival Rate
dc.subject.mesh	Humans
dc.subject.mesh	Oropharyngeal Neoplasms
dc.subject.mesh	Papillomaviridae
dc.subject.mesh	Papillomavirus Infections
dc.subject.mesh	Prognosis
dc.subject.mesh	Survival Rate
dc.title	Current state of play for HPV-positive oropharyngeal cancers.
dc.type	Journal Article
utslib.citation.volume	110
utslib.location.activity	Netherlands
utslib.for	1112 Oncology and Carcinogenesis
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	closed_access	*
dc.date.updated	2023-03-21T02:44:18Z
pubs.publication-status	Published
pubs.volume	110

Abstract:

Clinically, HPV-positive oropharyngeal cancers (OPCs) have been shown to have a distinct prognosis, compared to HPV-negative tumours, particularly in survival rates and responses to treatment. These patients have better survival chances and improved prognosis, indicating that a more exhaustive knowledge of these distinctions would aid in the discovery of clinical approaches for both HPV-positive and negative tumours. Furthermore, there is increasing evidence that HPV-related oropharyngeal cancers constitute an epidemiological, molecular, and clinical distinct form as compared to non-HPV related ones therefore, the treatment of these specific subtype of oropharyngeal cancers should adopt a distinct clinical treatment pipeline. Our review will examine the current approaches for the diagnosis and treatment of OPC and discuss the relevance of de-escalation clinical trials in progress.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/167915